Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Last Hour:
Last 24 Hours:

Gilead to drop simtuzumab and Crohn’s Disease treatment

Wednesday, November 2, 2016 1:01
% of readers think this story is Fact. Add your two cents.

US biopharmaceutical giant Gilead Sciences (NASDAQ:GILD) will drop simtuzumab from the ongoing development of its fatty liver disease treatment, GS-4997.

Gilead announced a couple of weeks ago that it would be advancing the treatment – also known as selonsertib – through to phase III trials following ‘encouraging’ phase II results.

As part of that recent study, selonsertib was tested both on its own and in combination with its investigational monoclonal antibody simtuzumab.

The latter did not have as big an impact as had been hoped and will not be taken forward into the upcoming phase III trials.

In its third quarter earnings report released yesterday (1 November), Gilead added that another compound, GS-5745, would not be progressed any further for the treatment of Crohn’s Disease.

Simtuzumab and GS-5745 are part of a range of products created using Abzena plc’s (LON:ABZA) Composite Human Antibody technology that its partners have been progressing in clinical development.

Abzena shares closed at 39.62p on Tuesday.

Story by ProactiveInvestors


We encourage you to Share our Reports, Analyses, Breaking News and Videos. Simply Click your Favorite Social Media Button and Share.

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Top Global


Top Alternative




Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.